Prasugrel: A Novel Thienopyridine Antiplatelet Agent. A Review of Preclinical and Clinical Studies and the Mechanistic Basis for Its Distinct Antiplatelet Profile

Joseph A. Jakubowski(Indiana Biosciences Research Institute), Lars Wallentin(Uppsala University), Hideo Naganuma(Daiichi-Sankyo (Japan)), Kenneth J. Winters(Eli Lilly (United States))

Cardiovascular Drug Reviews

December 1, 2007

10.1111/j.1527-3466.2007.00027.x

Cited by 249

Related Papers

Dabigatran versus Warfarin in Patients with Atrial Fibrillation

|New England Journal of Medicine|2009|11.2k

Ticagrelor versus Clopidogrel in Patients with Acute Coronary Syndromes

|New England Journal of Medicine|2009|7.1k

Risk of Bleeding With 2 Doses of Dabigatran Compared With Warfarin in Older and Younger Patients With Atrial Fibrillation

|Circulation|2011|1.1k

Efficacy and safety of dabigatran compared with warfarin at different levels of international normalised ratio control for stroke prevention in atrial fibrillation: an analysis of the RE-LY trial

|The Lancet|2010|1k

Clinical presentation, aetiology and outcome of infective endocarditis. Results of the ESC-EORP EURO-ENDO (European infective endocarditis) registry: a prospective cohort study

|European Heart Journal|2019|897